NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action…
CNM-Au8 treated participants in the HEALEY ALS Platform Trial with substantial neurofilament light (NfL) declines (CNM-Au8 NfL Responders) demonstrated significant…
Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP…
Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP…
NEW YORK, July 30, 2024 /PRNewswire/ -- The global telehealth market size is estimated to grow by USD 368.7 billion from…
Data partnership initiative expands access to critical healthcare data in ophthalmology, urology and neurologySAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE)…
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces an exclusive digital and advanced analytics collaboration with Healthcare Outcomes…
New clinical data presented at world's largest forum for dementia research confirms BrainCheck Assess is as accurate as widely-used MoCA Refreshed…
XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go…
- Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was…
